Clinical research has demonstrated that GLP-1R analogs improve the prognosis of cardiovascular disorders by raising the resting heart rate and decreasing arrhythmia in patients with heart failure (HF) [25,90]. This evidence concerns the gene GLP1R and hydrops fetalis.